You just read:

New Post-hoc Analysis Shows Adding UPTRAVI®▼ (selexipag) Versus Placebo Improved Long-term Clinical Outcomes Regardless of Time of Treatment Initiation, and Demonstrated an Even More Pronounced Treatment Effect When Initiated Early

News provided by

Actelion Pharmaceuticals Ltd

20 May, 2019, 08:00 BST